DAWN SWANN: Open Payments
NPI 1982797643 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$255 in 10 payments from 7 companies in 2025. Trend: 2023 $86 · 2024 $129 · 2025 $255
Food & beverage: $255
| Company | Payments | Amount |
|---|---|---|
| Fresenius USA Marketing, Inc. | 3 | $61 |
| AstraZeneca Pharmaceuticals LP | 2 | $46 |
| Vantive US Healthcare LLC | 1 | $38 |
| Vifor Pharma, Inc. | 1 | $33 |
| Calliditas Therapeutics US Inc. | 1 | $33 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $23 |
| Novartis Pharmaceuticals Corporation | 1 | $21 |
Products named: VELPHORO, FARXIGA, Renal - PD, Veltassa, TARPEYO, Tryvio, Vanrafia.
Industry payments across AL — which companies pay providers there.
